CA-BOLT
18.6.2024 15:03:34 CEST | Business Wire | Press release
Stellantis Financial Services US, the captive automotive finance company of Stellantis in North America, today announced a new partnership with bolt, the insurtech with the world’s largest technology-enabled insurance exchange, to support customers of Chrysler, Dodge, Jeep®, Ram, Fiat, and Alfa Romeo. bolt’s technology will enable Stellantis customers to purchase auto insurance through Stellantis brand websites and mobile apps with a panel of insurers’ products.
Through this unique partnership, the automotive insurance purchasing journey will be simplified and personalized, with custom coverage options available through multiple distribution channels. The offering will scale to include usage-based choices through the use of telematics, data and analytics.
“Stellantis customers today want choice, context, and simplicity when selecting their auto insurer,” said Mark Buffa, Managing Director of Insurance at Stellantis Financial Services US. “It’s important that insurance offerings keep up with customer demands. Partnering with bolt and their established insurer partners, we’re confident that customers and their vehicles will be better protected.”
“We are thrilled with this new partnership which reflects the Stellantis strategy to provide affordable insurance solutions and accident management solutions,” said Edouard de Lamarzelle, CEO of Stellantis Insurance.
Stellantis is focused on developing, engineering, manufacturing and scaling the best breakthroughs in all facets of sustainable mobility.
“Stellantis has an ambitious vision for how insurance can enhance their customers’ experience,” said Rob Bauer, Chief Strategic Growth Officer at bolt. “We’re honored to join Stellantis on this multi-year journey and help write the future of embedded insurance.”
By bridging the gap between all parties in the insurance ecosystem, bolt is developing modern methods of delivering insurance to customers at the point of need. bolt has grown its platform to include more than 100 insurance providers, including eight of the top 10 property and casualty insurers in the United States. With more than US$50 billion in quoted premiums on the platform annually, bolt offers over 6,000 insurance product variations and has licenses across all 50 states.
To learn more about Stellantis Financial Services, please visit www.stellantis-fs.com. To learn more about bolt, visit https://www.boltinsurance.com/.
About Stellantis Financial Services US
Stellantis Financial Services US (SFS) is wholly owned by Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP), one of the world’s leading automakers aiming to provide clean, safe and affordable freedom of mobility to all. SFS provides finance solutions for Stellantis' premier automotive brands in the United States including: Chrysler, Dodge, Jeep®, Ram, FIAT, and Alfa Romeo.
About bolt
bolt is the leading distribution platform for P&C insurance, uniting distributors and insurers to transform the way insurance is bought and sold.
The result is the world's largest tech-enabled exchange of insurance products, including two-thirds of America's leading insurers, helping businesses of all kinds distribute insurance, expand market reach, and meet more of the insurance and protection needs of customers.
For more information, visit boltinsurance.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618838215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom